The use of anti-TNF agents has dramatically changed the management of IBD in the last decades [56] but did not change the long-term course in certain subsets of paediatric CD patients [57] as well as the frequency of hospitalization in CD patients [58]. This evidence concerns the gene TNF and inflammatory bowel disease.